Amgen's cancer drug fails to improve survival rates

Now watching

Next video starts in : 7 Play

Amgen's cancer drug fails to improve survival rates

Amgen's cancer drug fails to improve survival rates
Replay video
Up next

This is not your ordinary workout

Unlock your personal NFL Now stream by signing in to NFL.com

Amgen's cancer drug fails to improve survival rates

by CNBC Videos 2:27 mins

Yaron Werber, Citi Investment Research, shares his thoughts on news Kyprolis failed to meet its primary endpoint of improving overall survival for patients with multiple myeloma.

View Comments (0)